Pharmabiz20h
Recce Pharma announces positive clinical data from phase II trial of RECCE 327 gel in acute bacterial skin & skin structure infections
Recce Pharma announces positive clinical data from phase II trial of RECCE 327 gel in acute bacterial skin & skin structure infections: Sydney Friday, February 21, 2025, 16:00 Hrs ...
FierceBiotech2d
Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial
Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...
The Pharma Letter2d
Recce Pharma reports positive Phase II trial of RECCE 327 Gel
Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) ...
Stockhead on MSN5d
Recce soars on phase II skin infection trial results
Recce Pharmaceuticals is up ~9% today after reporting positive patient data analysis from its phase II clinical trial of ...
The Daily Telegraph4d
Recce soars on phase II skin infection trial results
The company is forecasting a readout of the interim analysis by the end of 2025. Recce CEO James Graham said the global ABSSSI treatment market was a substantial commercial opportunity ...
Investing5d
Recce Pharmaceuticals receives positive Phase II results for R327G in bacterial skin infections
Recce Pharmaceuticals Ltd has received positive findings from a Phase II clinical trial evaluating RECCE® 327 Topical Gel (R327G) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), ...